Cymbalta and Neuromyopathy - a phase IV clinical study of FDA data

Summary:

Neuromyopathy is reported as a side effect among people who take Cymbalta (duloxetine hydrochloride), especially for people who are female, 60+ old, have been taking the drug for 1 - 6 months also take Requip, and have Gait disturbance.

The phase IV clinical study analyzes which people have Neuromyopathy when taking Cymbalta. It is created by eHealthMe based on reports of 145,249 people who have side effects when taking Cymbalta from the FDA, and is updated regularly.

What is Cymbalta?

Cymbalta has active ingredients of duloxetine hydrochloride. It is often used in depression. eHealthMe is studying from 154,972 Cymbalta users. Check the latest studies of Cymbalta.

What is Neuromyopathy?

Neuromyopathy (disease of both muscles and nerves) is found to be associated with 190 drugs and 347 conditions by eHealthMe. Check the latest studies of Neuromyopathy.

On Jun, 17, 2026

145,249 people reported to have side effects when taking Cymbalta.
Among them, 11 people (0.01%) have Neuromyopathy.

Among these 11 people:

How long have people been on Cymbalta when they have Neuromyopathy? *

What is the gender of people who have Neuromyopathy when taking Cymbalta? *

female: 81.82 %
male: 18.18 %

What is the age of people who have Neuromyopathy when taking Cymbalta? *

What are other drugs people take besides Cymbalta? *

What are other side effects people have besides Neuromyopathy? *

Head Injury: 4 people, 36.36%
Nausea (feeling of having an urge to vomit): 4 people, 36.36%
Agitation (state of anxiety or nervous excitement): 4 people, 36.36%
Fatigue (feeling of tiredness): 4 people, 36.36%
Dizziness: 4 people, 36.36%
Feeling Hot: 3 people, 27.27%
Proctalgia (pain in the rectum): 3 people, 27.27%
Dyskinesia (abnormality or impairment of voluntary movement): 3 people, 27.27%
Muscle Spasms (muscle contraction): 3 people, 27.27%
Mental Status Changes (general changes in brain function, such as confusion, amnesia (memory loss), loss of alertness, loss of orientation): 3 people, 27.27%

What are the existing conditions these people have? *

Pain: 3 people, 27.27%
Gait Disturbance: 3 people, 27.27%
Waldenstrom's Macroglobulinaemia (cancer affects small lymphocytes (white blood cells)): 1 person, 9.09%
Sleep Disorder: 1 person, 9.09%
Nervous System Disorder (a general class of medical conditions affecting the nervous system): 1 person, 9.09%
Narcolepsy (brain's inability to regulate sleep-wake cycles normally): 1 person, 9.09%
Intervertebral Disc Disorder (spinal disc disorder): 1 person, 9.09%
Hypersensitivity: 1 person, 9.09%
Headache (pain in head): 1 person, 9.09%
Erection Problems: 1 person, 9.09%

* Approximation only. Some reports may have incomplete information.

Do you take Cymbalta and have Neuromyopathy?

- Check whether Neuromyopathy is associated with a drug or a condition
- Predict drug outcomes for up to one year with AI
- Get an AI agent to monitor your drugs continuously

Related studies:

Effectiveness of, long term effects of, and alternative drugs to Cymbalta:

Cymbalta (154,972 reports)

Neuromyopathy treatments and more:

Neuromyopathy (1,398 reports)

Browse all side effects of Cymbalta:

a b c d e f g h i j k l m n o p q r s t u v w x y z

Browse all the drugs that are associated with Neuromyopathy:

Neuromyopathy (190 drugs)

Browse all the conditions that are associated with Neuromyopathy:

Neuromyopathy (347 conditions)

How the study uses the data?

The study uses data from the FDA. It is based on duloxetine hydrochloride (the active ingredients of Cymbalta) and Cymbalta (the brand name). Other drugs that have the same active ingredients (e.g. generic drugs) are not considered. Dosage of drugs is not considered in the study.

How to use the study?

DO NOT STOP MEDICATIONS without first consulting your doctor. If there are any serious or long term adverse effects discovered in the study, discuss the study with your doctor to ensure that proper medication management will be in place if applicable.

Who is eHealthMe?

With medical big data and proven AI/ML algorithms, eHealthMe provides a platform for everyone to run phase IV clinical trials. We study millions of patients and 5,000 more each day. Results of our real-world drug study have been referenced on 800+ peer-reviewed medical publications, including The Lancet, Mayo Clinic Proceedings, and Nature. Our analysis results are available to researchers, health care professionals, patients (testimonials), and software developers (open API).

WARNING, DISCLAIMER, USE FOR PUBLICATION

WARNING: Please DO NOT STOP MEDICATIONS without first consulting a physician since doing so could be hazardous to your health.

DISCLAIMER: All material available on eHealthMe.com is for informational purposes only, and is not a substitute for medical advice, diagnosis, or treatment provided by a qualified healthcare provider. All information is observation-only. Our phase IV clinical studies alone cannot establish cause-effect relationship. Different individuals may respond to medication in different ways. Every effort has been made to ensure that all information is accurate, up-to-date, and complete, but no guarantee is made to that effect. The use of the eHealthMe site and its content is at your own risk.

If you use this eHealthMe study on publication, please acknowledge it with a citation: study title, URL, accessed date.